Literature DB >> 7835195

The antiproliferative effect of fractionized radiation therapy: optimization of dosage.

M Velikay1, U Stolba, A Wedrich, P Datlinger, J Akramian, S Binder.   

Abstract

Fractionized radiation therapy with high-energy electrons have proven to reduce retinal detachment rate from 85% to 5% in the fibroblast model using a dosage of 3000 rad, starting from the first postoperative day. The purpose of this study is to gain more information about the therapeutic range of fractionized radiation therapy in experimental PVR. We therefore investigated the efficacy of this therapy when the total dose is reduced to 2000 rad. Irradiation treatment started on the first postoperative day. Eight weeks after cell implantation 5 of 14 eyes (35%) in the irradiated group and 15 of 16 eyes of the control group (93%) showed traction detachment. The statistically significant result proves a broad therapeutic range of fractionized radiation therapy in experimental PVR. We believe that a combination with antiinflammatory drugs could lead to a dose reduction in both therapies in patients.

Entities:  

Mesh:

Year:  1994        PMID: 7835195     DOI: 10.1007/bf01203855

Source DB:  PubMed          Journal:  Doc Ophthalmol        ISSN: 0012-4486            Impact factor:   2.379


  13 in total

1.  High-energy electrons used to inhibit experimental intraocular proliferation and detachment.

Authors:  S Binder; C Skorpik; P Paroussis; W Kulnig; R Menapace; E Prokesch
Journal:  Ophthalmologica       Date:  1987       Impact factor: 3.250

2.  Irradiation pretreatment before fibroblast implantation in experimental PVR.

Authors:  M Velikay; U Stolba; A Wedrich; P Datlinger; S Binder; L Handl-Zeller
Journal:  Int Ophthalmol       Date:  1993-08       Impact factor: 2.031

3.  The role of cellular proliferation in an experimental model of massive periretinal proliferation.

Authors:  D M Fastenberg; K R Diddie; K Dorey; S J Ryan
Journal:  Am J Ophthalmol       Date:  1982-05       Impact factor: 5.258

4.  The effects of injections of cultured fibroblasts into the rabbit vitreous.

Authors:  C A Hitchins; I Grierson; P S Hiscott
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1985       Impact factor: 3.117

5.  Treatment of intraocular proliferation with intravitreal injection of triamcinolone acetonide.

Authors:  Y Tano; D Chandler; R Machemer
Journal:  Am J Ophthalmol       Date:  1980-12       Impact factor: 5.258

6.  Oral colchicine for the treatment of experimental traction retinal detachment.

Authors:  M Lemor; J H Yeo; B M Glaser
Journal:  Arch Ophthalmol       Date:  1986-08

7.  Postoperative retinal fibrosis--a controlled clinical study of systemic steroid therapy.

Authors:  F Koerner; A Merz; B Gloor; E Wagner
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1982       Impact factor: 3.117

Review 8.  [Clinical and experimental results in the treatment of massive periretinal proliferation (MPP), a retinal detachment with a most unfavorable prognosis].

Authors:  S Binder
Journal:  Wien Klin Wochenschr Suppl       Date:  1982

9.  Intraocular daunorubicin for the treatment and prophylaxis of traumatic proliferative vitreoretinopathy.

Authors:  P Wiedemann; K Lemmen; R Schmiedl; K Heimann
Journal:  Am J Ophthalmol       Date:  1987-07-15       Impact factor: 5.258

10.  Action of x-rays on mammalian cells.

Authors:  T T PUCK; P I MARCUS
Journal:  J Exp Med       Date:  1956-05-01       Impact factor: 14.307

View more
  2 in total

1.  Inhibition of Mdm2 sensitizes human retinal pigment epithelial cells to apoptosis.

Authors:  Sujoy Bhattacharya; Ramesh M Ray; Edward Chaum; Dianna A Johnson; Leonard R Johnson
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-05-01       Impact factor: 4.799

2.  Bilateral rhegmatogenous retinal detachment after external-beam radiotherapy: just a coincidence?

Authors:  Laurent Kodjikian; Justus G Garweg; Jacques Fleury; François Rocher; Carole Burillon; Jean-Daniel Grange
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-03-24       Impact factor: 3.117

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.